No Detail Found!

Efficacy of High and Low Dose of BCG and Their Complications in Superficial Transtional Cell Carcinoma of Urinary Bladder

Author(s)
MUHAMMAD UMER Department of Urology, Mayo Hospital,Lahore-,Pakistan
FAISAL SHABBIR Department of Surgery, KMSMC, Sialkot, Pakistan
AMMAD AHMAD SIDDIQUI Department of Urology, Sahara Medical College,Narowal-,Pakistan
Abstract
Bladder cancer patients mostly (75%) present with non-muscle invasive bladder tumors. Aim: To compare tumor recurrence and side effects between high and low dose of BCG in NMIBC. Study Design: Randomized controlled trial. Methodology: Patients (n=30 each group) were enrolled with expected percentage of side effects with low dose (40 mg) as 2.5 % and high dose (80 mg) as 25.8%. Patients of all age groups with both genders having NMIBC (Ta, T1, Tis) and high grade tumors (G3) determined on histopathology of TURBT sample. Patients with history of renal transplant and chemotherapy were excluded. The difference between both groups was analyzed using Chi Square test with P- value of < 0.05 was considered statistically significant. Results: The mean age of patients in group A was 55.83 ± 9.17 and group B was 59.17 ± 8.13 years. There was no significant difference in the age of two groups (P= 0.142). There was no difference in gender distribution in two groups (P=0.688). Regarding the stage of tumor there were 13 cases of stage Ta and T1 in both groups. Conclusion: It was concluded that 40 mg dose of intra-vesical BCG in patients with NMIBC had lower recurrence and side effects as compared to higher dose of intra-vesical BCG.
Publication Details
Page(s) 91-92
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 05, Year: 2022

Request the full text from PASTIC

Keywords
Recurrence, side effects, Low dose BCG and High Dose BCG.
References
Jmal A,Siegel R,Fuji E .2010 .. CA Cancer Journal for Clinicians, 60(5) : 277-300.
Williams SK,Hoenig DM,Ghavamian R,Soloway M. .2010 .Intravesical therapy of bladdr cancer. Exprt opinion on Pharmacotherapy, 11(6) : 947-58.
Smaldone MC,DP MC,DR MC .2010 .Gingrich, Investigational therapies for non- muscle invasive bladder cancer. cancer Journal Urology, 19 : 371-83.
Andrew J. Lightfoot ,Henry M. Rosvear .2011 .Micha A.O'Donnll.Recognition and treatment of BCG failure in bladder cancer. Journal, 11 : 602-13.
Kowalski M.,Jones N.,Jewett M.,and Cuthbert. M. .2011 .Treatment with vicinium results in durable responses in patients with carcinoma in situ previously treated with bacille Calmette-Guerin (BCG). Urology, 11 : 602-13.
Babjuk M,Oosterlinck W .2011 .EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. EurpeaUrology, 59(6) : 997-1008.
Gontero P,Bohle A,Malmstrom A .2010 .The role of bacillus Calmette-Guerin in the treatment of non- muscle-invasive bladder cancer. Eur. Urol, 57 : 410-29.
Kapoor Rakesh,Singh Pratipal .2008 .BCG in the management of superficial carcinoma of bladder. Indian journal of urol, 24(1) : 72-76.
Timothy P Krosowik and Thomas S .2009 .Griffith.BCG Immunotherapy for urothelial carcinoma of bladder. , 1(2) : 281-88.
Shelly MD,Kynaston H,Court J. .2011 .A systemic view of intravesical BCG plus transurethral resection vs transurthral resection alone in TA AND T1 bladder cancer BJU Int. , 88(3) : 209-16.
Gakis G1,Todenhöfer T,Renninger M,Schilling D,Sievert KD .2011 .Schwentner Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score 1464. BJU Int., 10234 : 410X.
.2011 .. , 10234(11) : 1464-410X.
Sylvester RJ,Van der Meijden AP,Lamm DL,Irie Akira,Iwamura Masatsugu .2012 .Intravesical bacillus CalmetteGuerin reduces the risk of progression in patients with superficial bladder cancer.A met-analysis of published results of randomized clinical trials. J Urol, 168 : .
.2003 .Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. , 00607(4) : 8172-189.
Maurizio ,Paolo Gontero Willem,Oosterlinck Willem,High-risk Ta .2014 .T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology, 65(1) : 69-76.
Yokomizo A,Kanimoto Y,Okamura T,Ozono S,Koga H,Iwamura M,Tanaka H,Takahashi S,Tsushima T,Kanayama HO,Akaza H,Shinohara N,Mugiya S,Nomata K,Nakamura T,Naito S. Randomized,Urol S. Randomized .2015 .Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose Bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer J. , 10(15) : 1016-1.
Andius P.,S.Holmang. P. .2009 .BCG therapy in stage Ta /T1 bladder cancer prognostic factors for time to recurrence and progression. BJU international, 93 : 980-84.
Burger M,Catto JW,Dalbagni G .2013 .Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63(2) : 234-41.
0

Citations

0

Downloads

93

Views